New Agents in Treatment of Psoriatic Arthritis

Abdellatif , M. M.; El Gogary , A. K.; El Shishtawy , H. F.; Farrag , D. A.

doi:10.12816/0039681

Article Details

New Agents in Treatment of Psoriatic Arthritis

Authors:

Abdellatif , M. M. | El Gogary , A. K. | El Shishtawy , H. F. | Farrag , D. A.

Publisher:

Pan Arab League of Continuous Medical Education

Main Topics:

Medicine

Journal:

The Egyptian Journal of Hospital Medicine 2017 Vol.68 Issue 3, pp.1400-1404

Document Type:

Article

Publication Date:

7/2017

Document Language:

English

Document ID (Org No.):

107099

Frequency:

Quarterly

eISSN:

20907125

pISSN:

16872002

DOI:

10.12816/0039681

Descriptors:

Keywords:

Abstract:

 Background: psoriatic arthritis is a long term inflammatory arthritis. Psoriatic arthritis is leading to bone erosion, joint destruction and associated with nail diseases, dactylitis, enthesitis, sponnylitis and uveitis.
Aim of this study was to review the new lines of treatment for psoriatic arthritis with or without skin affection. Treatment, the underlying process in psoriatic arthritis is inflammation; so, treatments are directed to reduce and control inflammation. Although no clear correlation exists between joint inflammation and the skin in every patient, the skin and joint aspects of the disease often must be treated simultaneously. However, only certain therapies are effective for psoriasis and psoriatic arthritis. Systemic agents, can be used for both skin and joint manifestations, it includes methotrexate and ciclosporin. For the biologic agents, the tumour necrosis factor inhibitors such as adalimumab, etanercept, infliximab, golimumab and certolizumab are effective. Ustekinumab is a recently agent belonging to the group of anti-IL-12p40 antibodies and has been shown to be efficacious. Newer drugs in the treatment which have shown efficacy for both psoriasis and psoriatic arthritis consist of the anti-IL-17 agent, secukinumab, and a phosphodiesterase-4 inhibitor, apremilast. As well as the oral JaK inhibitor, tofacitinib, have very limited but promising data.

Article Details

New Agents in Treatment of Psoriatic Arthritis

Authors:

Abdellatif , M. M. | El Gogary , A. K. | El Shishtawy , H. F. | Farrag , D. A.

Publisher:

Pan Arab League of Continuous Medical Education

Main Topics:

Medicine

Journal:

The Egyptian Journal of Hospital Medicine 2017 Vol.68 Issue 3, pp.1400-1404

Document Type:

Article

Publication Date:

7/2017

Document Language:

English

Document ID (Org No.):

107099

Frequency:

Quarterly

eISSN:

20907125

pISSN:

16872002

DOI:

10.12816/0039681

Descriptors:

ARTHRITIS

PSORIASIS

RHEUMATOLOGY

INHIBITORS

PATIENTS

THERAPY

Psoriasis

Psoriatic Arthritis

Anti-TNF

Anti-IL-17

Small Molecules Inhibitors

Issues

Article Details

Authors: Abdellatif , M. M. | El Gogary , A. K. | El Shishtawy , H. F. | Farrag , D. A.

Publisher: Pan Arab League of Continuous Medical Education

Main Topics: Medicine

Journal: The Egyptian Journal of Hospital Medicine 2017 Vol.68 Issue 3, pp.1400-1404

Document Type: Article

Publication Date: 7/2017

Document Language: English

Document ID (Org No.): 107099

Frequency: Quarterly

eISSN: 20907125

pISSN: 16872002

DOI: 10.12816/0039681

Descriptors:

Issues

Authors:

Abdellatif , M. M. | El Gogary , A. K. | El Shishtawy , H. F. | Farrag , D. A.

Publisher:

Pan Arab League of Continuous Medical Education

Main Topics:

Medicine

Journal:

The Egyptian Journal of Hospital Medicine 2017 Vol.68 Issue 3, pp.1400-1404

Document Type:

Article

Publication Date:

7/2017

Document Language:

English

Document ID (Org No.):

107099

Frequency:

Quarterly

eISSN:

20907125

pISSN:

16872002

DOI:

10.12816/0039681